[Translation] Brinzolamide 10 mg/mL/ brimonidine 2 mg/mL eye drop suspension and Brinzolamide 10 mg/mL eye drop suspension + brimonidine 2 mg/mL eye drop Comparison of efficacy and safety in angle-type glaucoma/ocular hypertension
The purpose of this study was to demonstrate that a fixed combination (BID) [brimonidine 10 mg/mL/brimonidine 2 mg/mL suspension eye drops] was non-inferior to a non-fixed combination in reducing IOP ( BID) [Brinzolamide 10 mg/mL Suspension Eye Drops + brimonidine 2 mg/mL Eye Drops (Solution)].
Multi-Center Study Assessing Efficacy and Tolerability of TRAVATAN® Solution without BAK, containing Polyquad® Preservative (0.004% travoprost) in Patients Previously on latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution Monotherapy.
100 Clinical Results associated with Alcon-Couvreur NV
Login to view more data
0 Patents (Medical) associated with Alcon-Couvreur NV
Login to view more data
1
Literatures (Medical) associated with Alcon-Couvreur NV
31 Dec 1985·Farmaceutisch Tijdschrift voor Belgie
A new β-blocker
Author: Derkinderen, G.
A review with 7 references on the pharmacol. of betaxolol (I) [63659-18-7], discussing its selective β1-blocking activity and efficacy in the treatment of glaucoma.
100 Deals associated with Alcon-Couvreur NV
Login to view more data
100 Translational Medicine associated with Alcon-Couvreur NV
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.